Conmed (CNMD) Gains from Investment Securities (2022 - 2026)

Conmed (CNMD) has 5 years of Gains from Investment Securities data on file, last reported at -$113000.0 in Q2 2026.

• Quarterly Gains from Investment Securities rose 93.72% year-over-year to -$113000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.4 million (up 190.41% YoY) and the FY2025 annual result came in at $23.0 million, up 155.91% from the prior year.
• Gains from Investment Securities eased to -$113000.0 in Q2 2026, from $722000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $19.4 million in Q4 2025 to a low of -$27.0 million in Q3 2024.
• A 5-year average of -$1.2 million and a median of $722000.0 in 2026 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities slumped 1261.54% — and 2025, when it jumped 1495.32%.
• Tracing CNMD's Gains from Investment Securities over 5 years: stood at $2.5 million in 2022, then sank by 472.12% to -$9.4 million in 2023, then jumped by 113.01% to $1.2 million in 2024, then jumped by 1495.32% to $19.4 million in 2025, then plunged by 100.58% to -$113000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$113000.0 (Q2 2026), $722000.0 (Q1 2026), and $19.4 million (Q4 2025), per Business Quant data.